Literature DB >> 33355281

Study of clinical experience with different approaches to controlled ovarian hyperstimulation: a focus on safety and efficacy.

Svetoslav Stoev1, Ilko Getov2, Tanya Timeva3, Emilia K Naseva4, Hristina Lebanova5, Boyka Petkova6.   

Abstract

OBJECTIVES: Current retrospective cohort study analyses clinical database records of 4792 assisted reproduction procedures to assess the significance of target effectiveness endpoints from a safety perspective.
METHODS: Stimulation protocols with urinary, recombinant or combination of both types gonadotrophin preparations are compared according to the following primary endpoints: incidence of ovarian hyperstimulation syndrome (OHSS), cycle cancellation, follicle count, induced estradiol values, clinical pregnancy achieved and cycles reached embryo transfer/freezing. We have investigated the incidence of cases evaluated as 'risky for OHSS' by secondary efficacy endpoints (exogenous gonadotrophin exposure, luteinising hormone and progesterone values, oocyte yield, eggs with normal maturation). The following statistical methods were applied: descriptive statistics, Mann-Whitney U test, Kruskal-Wallis test, Pearson chi-square test, Fisher's exact test, binary logistic regression.
RESULTS: Only 16 cases (0.42%) of moderate and delayed OHSS were established. Three hundred and seven (8.6%) stimulation cycles have been cancelled, principally among urinary protocols. Although the clinical pregnancy rate does not differ significantly in compared groups, punctured follicle count, oocyte yield and progesterone level were higher for recombinant preparations, followed by combined and urinary protocols. Follicle count, mean estradiol and luteinising hormone levels are within the 'safe window' for all investigated groups, associated with minimised risk of stimulation cancellation. The mean follicle-stimulating hormone (FSH) dose was highest in urinary protocols at the same duration of stimulation compared with recombinant products. The younger age, bigger follicle count, oocytes yield, mature oocytes count, percentage of fertilised oocytes, more embryos transferred and the later day of embryo transfer are critical for both assisted reproduction techniques (ART) success rate and the safety profile of sterility treatment.
CONCLUSIONS: Safety surveillance of ART exceeds the incidence of OHSS. Suboptimal effectiveness of stimulation protocols may also jeopardise the well-being of ART patients. Gonadotrophin exposure, induced values of sex hormones, and quantity and quality of extracted oocytes should be considered to minimise any unintended suffering of treated couples. © European Association of Hospital Pharmacists 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  assisted reproduction; controlled ovarian hyperstimulation; drug effectiveness; gonadotrophin; medication safety; ovarian hyperstimulation syndrome

Mesh:

Substances:

Year:  2019        PMID: 33355281      PMCID: PMC7788199          DOI: 10.1136/ejhpharm-2019-001870

Source DB:  PubMed          Journal:  Eur J Hosp Pharm        ISSN: 2047-9956


  16 in total

1.  Circulating progesterone levels and ongoing pregnancy rates in controlled ovarian stimulation cycles for in vitro fertilization: analysis of over 4000 cycles.

Authors:  E Bosch; E Labarta; J Crespo; C Simón; J Remohí; J Jenkins; A Pellicer
Journal:  Hum Reprod       Date:  2010-06-10       Impact factor: 6.918

Review 2.  Ovarian hyperstimulation syndrome: definition, incidence, and classification.

Authors:  Einat Zivi; Alex Simon; Neri Laufer
Journal:  Semin Reprod Med       Date:  2010-11-16       Impact factor: 1.303

3.  Endocrine profile in serum and follicular fluid differs after ovarian stimulation with HP-hMG or recombinant FSH in IVF patients.

Authors:  J Smitz; A N Andersen; P Devroey; J-C Arce
Journal:  Hum Reprod       Date:  2006-11-16       Impact factor: 6.918

4.  Gonadotropin dose is negatively correlated with live birth rate: analysis of more than 650,000 assisted reproductive technology cycles.

Authors:  Valerie L Baker; Morton B Brown; Barbara Luke; George W Smith; James J Ireland
Journal:  Fertil Steril       Date:  2015-08-18       Impact factor: 7.329

5.  Clinical outcomes in relation to the daily dose of recombinant follicle-stimulating hormone for ovarian stimulation in in vitro fertilization in presumed normal responders younger than 39 years: a meta-analysis.

Authors:  M D Sterrenburg; S M Veltman-Verhulst; M J C Eijkemans; E G Hughes; N S Macklon; F J Broekmans; B C J M Fauser
Journal:  Hum Reprod Update       Date:  2010-09-15       Impact factor: 15.610

Review 6.  Infertility around the globe: new thinking on gender, reproductive technologies and global movements in the 21st century.

Authors:  Marcia C Inhorn; Pasquale Patrizio
Journal:  Hum Reprod Update       Date:  2015-03-22       Impact factor: 15.610

7.  Comparison of the efficacy and safety of a new recombinant human follicle-stimulating hormone (DA-3801) with follitropin-alpha (Gonal-F) in women undergoing controlled ovarian hyperstimulation for assisted reproductive technology.

Authors:  Shin Yong Moon; Young Sik Choi; Seung-Yup Ku; Seok Hyun Kim; Young Min Choi; Inn Soo Kang; Chung Hoon Kim
Journal:  J Obstet Gynaecol Res       Date:  2007-06       Impact factor: 1.730

8.  The concerns during assisted reproductive technologies (CART) scale and pregnancy outcomes.

Authors:  Hillary Klonoff-Cohen; Loki Natarajan
Journal:  Fertil Steril       Date:  2004-04       Impact factor: 7.329

9.  [A randomized, single-blind, parallel-controlled and multicentre study: compare the efficacy and safety of domestic and imported human recombinant FSH in WHO group Ⅱ anovulatory infertility].

Authors:  Y Z Zhou; H Shen; W L Zuo; Y H Xu; X H Deng; Y L Chen; Y Gao; X X Wang; W Xu; Q H Lai; H Shi; W Liu; Q He; F F He
Journal:  Zhonghua Fu Chan Ke Za Zhi       Date:  2016-04-25

10.  National, regional, and global trends in infertility prevalence since 1990: a systematic analysis of 277 health surveys.

Authors:  Maya N Mascarenhas; Seth R Flaxman; Ties Boerma; Sheryl Vanderpoel; Gretchen A Stevens
Journal:  PLoS Med       Date:  2012-12-18       Impact factor: 11.069

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.